Radiopharmaceutical developer Actinium Pharmaceuticals has named five clinicians and scientists to a new scientific advisory board that will guide development of its targeted radiotherapy pipeline.
The board will advise on clinical development strategy, trial design, patient selection, molecular imaging, and therapeutic combinations across Actinium’s solid tumor and hematologic cancer programs, according to the company. Those programs include ATNM-400, a HER3-targeted alpha radiotherapy now in a first-in-human phase I study in metastatic castration-resistant prostate cancer.
Board members include the following:
Karim Fizazi, MD, PhD, director general of the Centre Oscar Lambret in Lille, France, and professor of oncology at Paris-Saclay University.
Sergio Giralt, MD, deputy division head of hematologic malignancies at Memorial Sloan Kettering Cancer Center (MSK).
Jason Lewis, PhD, scientific director of the radiochemistry and molecular imaging probe core facility at MSK.
Michael Morris, MD, prostate cancer section head at MSK.
Neeta Pandit-Taskar, MD, chief of nuclear medicine at University of Pittsburgh Medical Center.
